TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Each subject must meet all of the following inclusion criteria during the screening process in order to participate in the study:~* Subjects must have a diagnosis of sickle cell disease (SS, SC, S-beta-thalassemia), other hemoglobinopathies, or hemolytic disorders, such as hereditary spherocytosis.~* Be at least 18 years old.~* Have a leg ulcer of at least 4 weeks (28 days) duration.~* Leg ulcer must be no smaller than 2.5 cm(2) and no larger than 100 cm(2).~* Provide written informed consent.~EXCLUSION CRITERIA:~Subjects meeting any of the following criteria during baseline evaluation will be excluded from entry into the study:~* Exposure to therapeutic nitric oxide, L-arginine, nitroprusside or nitroglycerine within the past 1 week.~* Subjects presenting with clinically diagnosed bacterial infection (e.g., osteomyelitis, pneumonia, sepsis or meningitis).~* Subjects who have a pre-existing methemoglobinemia (more than 2.5 percent), unless the cytochrome b5 reductase (methemoglobin reductase) is within normal limits and the methemoglobin is no greater than 3 percent)~* Patients who are currently enrolled in any other investigational drug study (this does not include observational or natural history protocols).~* Use of PDE5 inhibitors, such as sildenafil, 4 days prior to screening.~* Pregnant women (urine or serum HCG plus) or nursing mothers.~* The following list of drugs and agents may cause methemoglobinemia and should be avoided while on this study:~  * Anesthetics (local): Benzocaine, procaine, prilocaine, Anbesol, Orajel~ * Antimalarials: chloroquine, primaquine, quinacrine~ * Aniline dyes~ * Chlorates~ * Dapsone~ * Diarylsulfonylureas~ * Doxorubicin~ * Metoclopramide~ * Nitric and nitrous oxide~ * Nitrobenzenes (shoe and floor polish and in paint solvents)~ * Nitroethane (artificial nail remover, propellent, fuel additive)~ * Nitrofurantoin (furadantin)~ * Pyridium (phenazopyridine)~ * Phenacetin (acetaminophen)~ * Phenylhydrazine~ * Rasburicase~ * Sulfonamides (sulfacetamide, sulfamethoxazole, sulfanilamide, sulfapyridine)~    * If a subject participant meets exclusion criteria while participating in the trial, then the subject will be removed from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Subjects with Type 2 Diabetes Mellitus,~* Subjects on antidiabetic treatment (oral and/or insulin therapy) for \> 6 months,~* Subjects who require a basal long-acting insulin for the control of hyperglycaemia,~* HbA1c values \> 7.0% and \< 12 %,~* BMI \< 40 kg/m².~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of RA (2010 American College of Rheumatology \[ACR\]/European League Against Rheumatism \[EULAR\] criteria for RA), and are ACR functional class I-III.~* Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints \[SJC66\]) and ≥6 tender joints (from a tender joint count based on 68 joints \[TJC68\]) at screening and Day 1~* Ongoing treatment with a stable prescription of 1 or 2 csDMARDs~* Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for the treatment of RA to which they have had an inadequate response or intolerance~Key Exclusion Criteria:~* Previous treatment with any janus kinase (JAK) inhibitor~NOTE: Other protocol Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
- Filgotinib 100 mg (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed adenocarcinoma of the prostate with lymphatic, bone, visceral or soft tissue metastases (stage IV) No prostatic transitional cell or small cell carcinoma PSA greater than 4.0 ng/dL Measurable or evaluable disease by PSA OR Bidimensional disease on physical exam or radiologic imaging studies Testosterone less than 50 mg/L if prior hormonal therapy with gonadal ablation (LHRH analogues) or estrogens No previously irradiated or new CNS metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: Greater than 6 months Hematopoietic: WBC at least 3,000/mm3 Absolute lymphocyte count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 mg/dL Hepatic: Bilirubin less than 2.0 mg/dL No hepatic disease Renal: Creatinine less than 2.5 mg/dL No symptomatic urinary tract infection Cardiovascular: No New York Heart Association class III or IV heart disease Pulmonary: No acute or chronic asthma No chronic obstructive pulmonary disease Other: No history of autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis) No other concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer No active acute or chronic infection HIV negative No other medical or psychological condition that would preclude study Adequate peripheral vein access Hepatitis B surface antigen negative Hepatitis C negative~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior biologic therapy and recovered No other concurrent immunotherapy Chemotherapy: At least 6 weeks since prior chemotherapy and recovered No concurrent chemotherapy Endocrine therapy: See Disease Characteristics Greater than 4 weeks since prior flutamide At least 6 weeks since prior bicalutamide Concurrent gonadal androgen suppression with LHRH analogues allowed unless androgen refractory disease At least 6 weeks since prior steroids No concurrent steroids Radiotherapy: See Disease Characteristics At least 6 weeks since prior radiotherapy to the prostate (12 weeks since strontium 89) and recovered No concurrent radiotherapy Surgery: Prior surgical castration allowed Other: No concurrent immunosuppressants (e.g., azathioprine or cyclosporine)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Effect in Second Stage Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with a maximum of 2 class of antihypertensive drugs~Exclusion Criteria:~* Current serum-creatinine \>3 mg/dL, Current serum-potassium \>5.5 mmol/L, 16.~* Pregnant or lactating women or women of childbearing potential who were not protected from pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Candesartan cilexetil 16mg monotherapy
- 2 (Type: EXPERIMENTAL): Candesartan cilexetil 16mg/HCT combination therapy
- 3 (Type: ACTIVE_COMPARATOR): candesartan cilexetil 32mg monotherapy
- 4 (Type: EXPERIMENTAL): Candesartan Cilexetil 32 mg/HCT combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients complaining of blurred vision and/or acute-onset paracentral scotoma during the last month without any visible fundus change along with typical SD-OCT and OCTA findings.~Exclusion Criteria:~* The presence of noticeable changes in the fundus examination,~* Any optic media opacity that may cause artefacts on OCTA images and interfere with quantitative measurements of the DCP vessel density,~* Complaining of paracentral scotoma lasting more than 1 month (in order to exclude chronic changes in the retinal tissue),~* Presence of atrophic changes in INL or ONL on cross-sectional B-scan SD-OCT

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Only electromagnetic stimulation (Type: ACTIVE_COMPARATOR): Only rEMS was preferred as the initial step
- Combined with electromagnetic stimulation and PRP (Type: ACTIVE_COMPARATOR): Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
- Natural course (Type: NO_INTERVENTION): Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis or renal limited vasculitis~* Male and female subjects, aged at least 18 years, with new or relapsed AAV where treatment with cyclophosphamide or rituximab would be required~* Use of adequate contraception during, and for at least the three months after, any administration of study medication is required~* Positive indirect immunofluorescence (IIF) test for P-ANCA or C-ANCA, or positive ELISA test for anti-proteinase-3 (PR3) or anti-myeloperoxidase (MPO) at screening~* Have at least one major item, or at least 3 other items, or at least 2 renal items on the Birmingham Vasculitis Activity Score (BVAS) version 3~* Estimated glomerular filtration rate (eGFR) ≥ 20 mL per minute~Exclusion Criteria:~* Severe disease as determined by rapidly progressive glomerulonephritis, alveolar hemorrhage, hemoptysis, rapid-onset mononeuritis multiplex or central nervous system involvement~* Any other multi-system autoimmune disease~* Medical history of coagulopathy or bleeding disorder~* Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil, or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1~* Received intravenous corticosteroids, \>3000 mg methylprednisolone equivalent, within 12 weeks prior to screening~* Received an oral daily dose of a corticosteroid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to the screening visit~* Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred; received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or plasma exchange within 12 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CCX168 low dose plus standard of care (Type: ACTIVE_COMPARATOR): Capsule, 10 mg, twice daily + standard of care for 12 weeks
- CCX168 high dose plus standard of care (Type: ACTIVE_COMPARATOR): Capsule, 30 mg, twice daily + standard of care for 12 weeks
- Placebo, twice daily + standard of care (Type: PLACEBO_COMPARATOR): Capsule, placebo, twice daily + standard of care for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age≥18 years~* PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions~* NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle)~Exclusion Criteria:~* intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy~* previous intravitreal injection of ranibizumab or bevacizumab in either eye~* previous intravitreal corticosteroids injection in either eye~* pregnancy or current oral contraceptive intake~* usage of clopidogrel bisulfate or coumadin~* uncontrolled hypertension and cardiac disease~* uncontrolled renal or liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ranibizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer.~* Patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the penultimate chemo regimen.~* For the last chemotherapy course prior to enrolment on the study, patients must have demonstrated an objective stable maintained response (partial or complete response) and this response needs to be maintained until completion of chemotherapy.~* Patients must be treated on the study within 8 wks of completion of their final dose of the platinum containing regimen.~Exclusion Criteria:~* Previous treatment with PARP inhibitors including AZD2281~* Patients with low grade ovarian carcinoma.~* Patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study~* Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD2281
- 2 (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute lithiasic cholecystitis low or moderately severe (confined to the gall bladder)~* Requiring early cholecystectomy (progression of symptoms \<5 days~* In an adult patient (\>18 years)~* For each patient included the consent form must have been read, understood and signed.~Exclusion Criteria:~* Severe acute cholecystitis (with organ dysfunction)~* Acalculous cholecystitis~* Biliary peritonitis~* Abscess perivesicular~* Cholangitis~* Acute Pancreatitis~* Septic shock~* Stone of bile duct~* Physical or mental state does not allow participation in the study~* Contraindication to surgery~* Classification ASA (American Society of Anesthesiologists) IV-V or life expectancy \<48 hours~* Suspected pre-or intraoperative cancer of the gallbladder~* Pregnancy or breastfeeding~* Treatment course with methotrexate, imidazole~* Known history of allergy to Augmentin ®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amoxicillin clavulanic acid (Type: ACTIVE_COMPARATOR): Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
- No medication (Type: OTHER): no postoperative antibiotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 or older receiving methadone treatment at Morse Clinic in Raleigh or Zebulon, NC.~* Able to provide informed written consent to participate in the pilot study.~* Receiving a stable methadone dose between 5 mg and 160 mg.~* Having all negative drug tests (except for prescribed methadone and ethanol) at the OTP for the past 12 months.~* No missed call-backs in the past 12 months.~* No signs/symptoms of a co-occurring major mental illness (i.e., thought disorder, thoughts of harm to self or others, delusions or hallucinations, cognitive impairment compromising informed consent to study procedures and requirements).~* Meeting the federal and state regulations for eligibility to receive between 6- and 13-days of take-home methadone and receiving this level of take-home doses at the time of study enrollment.~* If female, using adequate birth control methods.~Exclusion Criteria:~* Have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study.~* Have chronic pain requiring ongoing pain management with opioid analgesics.~* Prisoner status or pending legal action that could prevent participation in study activities~* Legal order for treatment (e.g., parole, probation, or pre-trial)~* Pregnant or breastfeeding at the time of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pharmacy-based methadone treatment (Type: EXPERIMENTAL): Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B \& C - enrollment closed)~* Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B \& C - enrollment closed)~* Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)~Exclusion Criteria:~* Known central nervous system lymphoma~* Participants with nodular lymphocyte-predominant Hodgkin Lymphoma~* Prior allogeneic stem cell transplantation (SCT)~* Chest radiation ≤ 24 weeks prior to first dose~* Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Cohort A, B, C and D) (Type: EXPERIMENTAL): Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete